跳至主要内容
临床试验/NCT02665728
NCT02665728已完成2 期

A Safety and Efficacy Evaluation of BLI400 Laxative in Constipated Adolescent Subjects

Braintree Laboratories3 个研究点 分布在 1 个国家目标入组 33 人开始时间: 2015年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
33
试验地点
3
主要终点
Treatment Response

研究概览

简要总结

The objective of this study is to evaluate the safety and efficacy of BLI400 laxative in constipated adolescent subjects.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
12 Years 至 17 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Male or female subjects at between 12-17 years of age
  • Weight more than 40 kg (88 lbs.).
  • Constipated, defined by the following criteria
  • Fewer than 3 spontaneous defecations per week and at least one of the following symptoms for at least 12 weeks (which need not be consecutive) in the preceding 12 months:
  • Straining during > 25% of defecations
  • Lumpy or hard stools in > 25% of defecations
  • Sensation of incomplete evacuation for > 25% of defecations
  • Loose stools are rarely present without the use of laxatives
  • There are insufficient criteria for irritable bowel syndrome - loose (mushy) or watery stool in the absence of laxative use for more than 25% of bowel movements
  • Criteria A, B and C must be fulfilled for the last 12 weeks with symptom onset at least 6 months prior to diagnosis.
  • Otherwise in good health, as determined by physical exam and medical history
  • If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, intrauterine device, double-barrier method, depot contraceptive, sterilized, or abstinence)
  • Negative urine pregnancy test at screening, if applicable
  • In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study

排除标准

  • Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
  • Subjects who have had major surgery 30 days before Visit 1; appendectomy or cholecystectomy 60 days before Visit 1; abdominal, pelvic, or retroperitoneal surgery 6 months before Visit 1; bariatric surgery or surgery to remove a segment of the GI tract at any time before Visit 1
  • Subjects with hypothyroidism that is being treated and for which the dose of thyroid hormone has not been stable for at least 6 weeks at the time of Visit 1
  • Subjects taking laxatives, enemas or prokinetic agents that refuse to discontinue these treatments from Visit 1 until after completion of Visit 3
  • Subjects who are pregnant or lactating, or intend to become pregnant during the study
  • Subjects of childbearing potential who refuse a pregnancy test
  • Subjects who are allergic to the study medication
  • Subjects taking narcotic analgesics or other medications known to cause constipation
  • Subjects who, in the opinion of the Investigator, should not be included in the study for any reason, including inability to follow study procedures
  • Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
  • Subjects with an active history of drug or alcohol abuse
  • Subjects have been hospitalized for a psychiatric condition or have made a suicide attempt during the 2 years before Visit 1
  • Subjects who withdraw consent at any time prior to completion of Visit 1 procedures

研究组 & 干预措施

BLI400

Experimental

BLI400 Laxative

干预措施: BLI400 Laxative (Drug)

结局指标

主要结局

Treatment Response

时间窗: 4 weeks

Overall treatment response is defined as weekly response in at least 2 out of 4 weeks. Weekly response is defined as greater than or equal to 3 spontaneous bowel movements during a week.

次要结局

未报告次要终点

研究者

发起方
Braintree Laboratories
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验

A Safety and Efficacy Evaluation of BLI400 Laxative... | 临床试验